Chromadex Corp.
(NASDAQ : CDXC)

( )
CDXC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Process Industries » Chemicals Specialty
symbolcompany%chnglast%shortavg$volume
LINLinde Plc -0.02%328.560.0%$429.84m
DOWDow, Inc. 0.02%60.752.5%$307.17m
APDAir Products & Chemicals, Inc. -0.05%291.221.5%$222.39m
ALBAlbemarle Corp. -0.02%233.623.4%$201.35m
LYBLyondellBasell Industries NV -0.08%102.732.8%$172.56m
ECLEcolab, Inc. -0.04%215.941.6%$164.29m
AVTRAvantor, Inc. 0.00%37.710.0%$147.53m
ROGRogers Corp. 0.02%273.401.2%$69.68m
DQDaqo New Energy Corp. -0.14%42.310.0%$58.22m
LTHMLivent Corp. 0.00%24.580.0%$54.44m
AMRSAmyris, Inc. 0.00%4.994.0%$33.78m
CHXChampionX Corp. 0.00%24.570.0%$29.82m
ASHAshland Global Holdings, Inc. 0.03%105.733.5%$27.89m
GEVOGevo, Inc. 0.00%4.100.9%$26.80m
PEIXAlto Ingredients, Inc. 0.00%5.171.6%$23.97m

Company Profile

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.